Viewing nowCombinationAlls Diphin Tablet 5/20 mg
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Palmgen Science Co., Ltd.

MFDS item code 201404769 · Approved 2014.10.17 · Insurance code 670103690
Treatment of essential hypertension not controlled with monotherapy
This medicine is used to effectively lower blood pressure in patients with essential hypertension whose blood pressure is not adequately controlled by monotherapy with amlodipine or olmesartan medoxomil.
Take 1 tablet of this medicine once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended to adjust the dose using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using the individual components, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows: - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. Administration of this medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients receiving dialysis. Monitoring of potassium and creatinine levels is recommended for patients with moderate renal impairment. ∘Patients with reduced effective circulating blood volume: For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose with careful monitoring of their condition. ∘Patients with hepatic impairment: Use caution when administering this medicine to patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2, Patients who should not receive this medicine, under Precautions for Use.) ∘Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.
∘Children: The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.
This medicine may cause serious harm to the fetus and newborn if taken during the second and third trimester of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. Patients who are allergic to the active ingredients of this medicine or similar class medications, pregnant or breastfeeding women, individuals with severe liver impairment or aortic stenosis, patients with biliary obstruction, those on renal dialysis, individuals in shock, and certain diabetic patients with renal impairment should not take this medicine. Caution is required for patients with low blood pressure due to inadequate fluid or sodium, as blood pressure may drop further upon initiation of this drug, and proper interventions should be obtained if blood pressure becomes too low. This medication may cause rapid vasodilation leading to hypotension. Therefore, patients with severe aortic stenosis should use this drug with caution. Patients with severe coronary artery disease should be cautious when initiating or adjusting the dose of this medication due to the risk of exacerbating angina or myocardial infarction. This medication should be used with caution in patients with heart failure, and those with impaired renal function should be closely monitored for changes in renal function during treatment. Patients with poor liver function should also exercise caution while taking this medication. While taking this medicine, side effects such as dizziness, headache, hypotension, edema, dyspepsia, and rash may occur. If any unusual symptoms arise, consult with a healthcare professional. Particularly, caution is needed if combined with potassium-sparing diuretics or potassium supplements, as this may raise serum potassium levels. Avoid taking this medication during pregnancy, and consult with a physician to switch to other treatments if pregnancy is planned or confirmed. For breastfeeding mothers, since this medication can be transmitted through breast milk and may affect infants, either breastfeeding should be discontinued or the medication should be stopped. This medication is not recommended for children under 18 years of age as its safety and efficacy have not been established in this population. Elderly patients should start at a lower dose due to the possibility of reduced renal and liver function and should be monitored closely. In case of overdose, blood pressure may drop significantly and heart rate may increase; immediate medical attention is necessary.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture. The storage temperature should be maintained at room temperature between 1°C and 30°C, avoiding extremes of heat or cold.
White, round film-coated tablets
30 tablets/Alu-Alu (10 tablets/Alu-Alu packaging X 3)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Palmgen Science Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.